MVP and neoplasm: Studies on drugs targeting ARF6 and its upstream or downstream molecules have demonstrated that the eIF4A inhibitor silvestrol, which blocks the translation of ARF6 mRNA, and the MVP inhibitor statin, which blocks ARF6 activity, inhibit ARF6-based tumor malignancy.